Cargando…

Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study

Objectives: Besides their proven effectivity in decreasing the risk of cardiovascular events, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARBs) are likely to possess anti-inflammatory properties as well. This study aims to investigate whether the use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sluijsmans, Dorien M. C. F., Rohrich, Daphne C., Popa, Calin D., van den Bemt, Bart J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124323/ https://www.ncbi.nlm.nih.gov/pubmed/34063142 http://dx.doi.org/10.3390/jcm10091985

Ejemplares similares

Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study
por: Rohrich, Daphne C., et al.
Publicado: (2021)

Atherosclerosis in Rheumatoid Arthritis
por: González-Gay, Miguel A., et al.
Publicado: (2012)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

Disentangling Rheumatoid Arthritis Patients’ Implicit and Explicit Attitudes toward Methotrexate
por: Linn, Annemiek J., et al.
Publicado: (2016)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial
por: van Heuckelum, Milou, et al.
Publicado: (2021)

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
por: van der Togt, Céleste J T, et al.
Publicado: (2022)

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
por: Wientjes, Maike H M, et al.
Publicado: (2022)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
por: van Heuckelum, Milou, et al.
Publicado: (2019)

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
por: den Broeder, Alfons A., et al.
Publicado: (2017)

A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management
por: Dessein, Patrick H., et al.
Publicado: (2015)

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
por: van den Bemt, Bart JF, et al.
Publicado: (2011)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
por: den Broeder, Alfons A, et al.
Publicado: (2013)

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Rheumatoid Arthritis Disadvantages Younger Patients for Cardiovascular Diseases: A Meta-Analysis
por: Fransen, Jaap, et al.
Publicado: (2016)

Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals
por: Popa, Calin D., et al.
Publicado: (2012)

Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis
por: Kacsándi, Dorottya, et al.
Publicado: (2023)

Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
por: Chalan, Paulina, et al.
Publicado: (2015)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial
por: Pouls, Bart P H, et al.
Publicado: (2022)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
por: van Herwaarden, Noortje, et al.
Publicado: (2015)

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
por: van Boheemen, Laurette, et al.
Publicado: (2021)

Rheumatoid arthritis: what do MRI and ultrasound show
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2017)

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study
por: Arts, Elke, et al.
Publicado: (2012)

Determinants of drug prices: a systematic review of comparison studies
por: Janssen Daalen, Jules M, et al.
Publicado: (2021)

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients
por: Damen, Michelle S. M. A., et al.
Publicado: (2018)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Modern Management of Rheumatoid Arthritis
por: Huskisson, E. C., et al.
Publicado: (1978)

Rheumatoid Arthritis Illustrated
por: Somerville, W. F.
Publicado: (1909)

Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Soós, Boglárka, et al.
Publicado: (2022)

Why do we not have a cure for rheumatoid arthritis?
por: El-Gabalawy, Hani D, et al.
Publicado: (2002)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Bone Effects of Biologic Drugs in Rheumatoid Arthritis
por: Corrado, Addolorata, et al.
Publicado: (2013)

Drug-related problems in patients with rheumatoid arthritis
por: Ma, Shu Ning, et al.
Publicado: (2019)

Predictors for response to electronic patient-reported outcomes in routine care in patients with rheumatoid arthritis: a retrospective cohort study
por: Wiegel, Jimmy, et al.
Publicado: (2023)

RHEUMATOID FACTOR AND THE PATHOGENESIS OF RHEUMATOID ARTHRITIS
por: Mellors, Robert C., et al.
Publicado: (1961)

Cannot write session to /tmp/vufind_sessions/sess_5o2fmigdt6daeaip0tdro33r0d